Studienzentrum Dr. Andreas Schwittay
- Address
- lock Available on a paid plan
Studienzentrum Dr. Andreas Schwittay - Gastrointestinal Disorders Research
Studienzentrum Dr. Andreas Schwittay is a clinical research facility specializing in gastrointestinal therapeutic areas, with particular expertise in functional bowel disorders. The center focuses on evaluating novel therapeutic interventions for patients suffering from chronic digestive conditions that significantly impact quality of life.
- Irritable Bowel Syndrome with diarrhea-predominant symptoms (IBS-D)
- Probiotic and microbiome-based therapeutic interventions
- Symptom management and patient-reported outcomes in functional GI disorders
The research center conducts rigorous randomized, double-blind, placebo-controlled trials to assess both efficacy and safety profiles of investigational treatments. Their work encompasses the evaluation of living bacterial therapies and their role in modulating gastrointestinal function, with emphasis on measuring improvements in symptom frequency, severity, and overall tolerability in patients with chronic bowel conditions.
Site Overview
Activity Indicator
Last 6 months
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1SymbioPharm GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studienzentrum Dr. Andreas Schwittay
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Escherichia coli DSM 17252 in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial | SymbioPharm GmbH | Phase III | Recruiting | Nov 2019 | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.